top of page

OUR TEAM

With passion and a wealth of experience, our leadership team is committed to the development of innovative therapies, the creation of new business models, and driving high-value strategic collaborations.

Core Management Team

CEO Amy Huang

Amy Huang
CEO, Founder

Ms. Huang previously served as Vice President at Taian Biotechnology Co., Ltd., bringing a background as a seasoned venture capital fund manager with exceptional insight into innovative technologies. Her investment expertise spans a wide range of areas, including novel drug development, pharmaceutical formulations, biosimilars, API manufacturing, medical devices, and diverse disease fields such as neurodegeneration, diabetes, oncology, precision medicine, inflammation, and infection.

 

Leveraging her professional strategic planning capabilities, Ms. Huang has successfully led numerous portfolio companies through significant milestones, including financing, strategic partnerships, scaling operations, and corporate transformations. 


Currently, she is responsible for corporate management strategic planning, innovative technology development, organizational structure design and optimization, and overseeing external business development and collaborations, all with the aim of driving the company's robust growth and sustainable development. As the founder of our company, Ms. Huang further guides us towards new horizons with her long-term vision and unwavering conviction.

Scientific & Administrative Team

IMG_0385_edited.jpg

Senior Scientist

YuYu Shiung, PhD

YuYu is a Senior Scientist at Topmunnity, where he leads antibody drug development projects. With extensive experience from various biotechnology firms and Academia Sinica, YuYu brings a unique blend of technical expertise in the preclinical development of novel monoclonal antibody drugs and antibody-drug conjugates. His specialization covers genetic engineering, vector and antigen design, antibody engineering, and the development and validation of diverse analytical methods.

Mark_edited.jpg

AI Algorithm Engineer

Mark Chen

Mark Chen is an AI Algorithm Engineer at Topmunnity, where he is responsible for constructing algorithmic platforms that combine molecular dynamics with AI deep learning and machine learning, optimizing candidate drugs, and developing algorithms for human medical signal processing and protein structure-function computation, along with related validation. Mark specializes in computer-aided drug screening, molecular simulation, bioinformatics analysis, and new drug development. He has extensive experience in drug structure analysis, target discovery, and ADMET prediction, and has participated in multiple cancer and viral drug development projects.

Hsuan profile_edited.jpg

AI Algorithm Engineer

Hsuan Yang

Hsuan Yang is an AI Algorithm Engineer at Topmunnity where he is responsible for executing AI technology platform antibody simulation design. Hsuan's expertise lies in data processing, biological image processing, machine learning, and software product development projects.

陳佩旻_照片.jpeg

Senior Manager,

Drug Development & Regulatory Affairs

Evelyn Chen, PhD PMP

Evelyn Chen is a Senior Manager, Drug Development & Regulatory Affairs, PMP at Topmunnity, where she is responsible for drug development planning and project management, as well as planning new drug product development applications from preclinical to IND stages, and managing new drug development regulatory affairs projects, while providing regulatory strategy advice. Evelyn specializes in regulatory document management, regulatory strategy formulation, translational research, GLP/GCLP regulatory compliance testing, and NGS gene testing and laboratory management.

andrea yang_edited_edited.jpg

Finance Manager

Andrea Yang

Andrea Yang is a Finance Manager at Topmunnity, where she is responsible for the company's overall accounting, financial planning and management, cost management, and budget preparation and control. She also plays a key role in establishing and perfecting the company's financial monitoring system for effective internal control, ensuring compliance with regulatory laws and policies, and participating in the planning and execution of company investments and significant business activities. Andrea specializes in Sarbanes-Oxley Act corporate compliance audits and consulting, guiding Taiwanese companies through emerging stock market and IPO reviews, corporate internal control consulting and auditing, financial statement analysis and auditing, and tax planning and auditing.

Scientific Advisors

Ph.D. in Statistics from the University of Minnesota
Fellow of the American Statistical Association
Founder of the Department of Biostatistics at Rutgers New Jersey Medical School
Adjunct Director of Biostatistics in Cancer Research at Rutgers New Jersey Medical School
Consultant to the U.S. Department of Health and Human Services
Early promoter and lifetime member of the Pan-Pacific Association of Quantitative Methods
Pioneer in the "sample size re-estimation" method, advocating for its use in achieving "consistency"
Author of statistical principles for testing "bridging trials"
Honorary retired professor at Rutgers University since 2020

bottom of page